Day: June 12, 2023

VANCOUVER, British Columbia, June 12, 2023 (GLOBE NEWSWIRE) — Arbor Metals Corp. (“Arbor” or the “Company”) (TSXV: ABR, FWB: 432) announces the successful completion of a detailed spectral analysis of the Jarnet Lithium project located in the James Bay region of Quebec. This comprehensive study marks a significant milestone in advancing our understanding of the lithium potential in this promising area.

In the analysis conducted by our team of experts, four discrete datasets were meticulously correlated with 81 lithium-bearing rock chip samples collected at the Jarnet site. Additionally, we carefully examined the presence of significant spodumene-bearing pegmatites on adjoining projects. By integrating multiple data sources, including resistivity measurements and gas emissions, we aimed to gain comprehensive insights into the lithium-rich geological formations of the area.

The findings from this study hold great promise for the Jarnet Lithium project and the surrounding region. The spectral analysis allowed us to identify and characterize various lithological units indicative of lithium mineralization potential. These valuable insights will guide our exploration efforts and decision-making processes as we progress with the project.

“We are thrilled to have completed this comprehensive spectral analysis of the Jarnet Lithium project,” said Mark Ferguson, CEO of Arbor Metals. “The results obtained from this study provide us with a solid foundation to further explore the lithium potential in this region and advance our understanding of the geological factors influencing the presence of lithium-bearing deposits.”

The Jarnet Lithium project, initially identified by the Company in 2021, has consistently demonstrated strong lithium prospects, making it a key focus area for our company’s growth strategy. This recent analysis further confirms the project’s potential and reinforces our commitment to unlocking its full potential.

Arbor remains dedicated to responsible and sustainable exploration practices. As we progress with the Jarnet Lithium project, we prioritize environmental stewardship and community engagement, ensuring that our activities align with the highest social and environmental responsibility standards.

Moving forward, Arbor will leverage the valuable insights gained from this spectral analysis to inform our exploration program at the Jarnet site. We remain committed to unlocking the significant lithium potential in the St. James Bay region and look forward to updating our stakeholders as we achieve key milestones in our journey.

Dr. Peter Born, P.Geo., is the designated qualified person as defined by National Instrument 43-101 and is responsible for and has approved the technical information in this release.

About Arbor Metals Corp.

Arbor Metals Corp. is a mining exploration company focused on developing high-value, geographically significant mineral projects around the world. Arbor is paving the way for advanced mineral exploration as it oversees world-class mining projects. The company is confident that combining quality projects with proven strategies and a dedicated team will yield exceptional outcomes. Arbor currently oversees three outstanding mineral projects.

The Jarnet lithium project, located in the James Bay region of Quebec, comprises 47 map-designated claims, covering an area of approximately 3,759 hectares. The Jarnet project is contiguous to the Corvette-FCI property, where diamond drilling has confirmed significant lithium mineralization, and represents one of the highest-profile lithium exploration projects in the sector.

A map accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a4b4b1a7-74fa-413a-9c07-0253f02038d1

For further information, contact Mark Ferguson, Chief Executive Officer, at info@arbormetals.com or visit the Company’s website at www.arbormetalscorp.com.

On behalf of the Board,

Arbor Metals Corp.

Mark Ferguson, Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When or if used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the development of the Jarnet Lithium Project, the assessment of samples from that Project, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

Contact Data

CONTACT:

MRKT360 INC

https://mrkt360.com

Alex Zertuche

alexz@mrkt360.com

For E.S.T Office Hours, Call 1 416-477-0587

GlobeNewswire Distribution ID 8855286

PRESS RELEASE

Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness

• New leading gene therapy company created combining late-stage X-linked retinitis pigmentosa (XLRP) program from AGTC, a preclinical program spun out from the University of Oxford and a second preclinical program to deliver a broad ophthalmic development pipeline
• Led by a highly experienced leadership team including David Fellows, Dr. Nadia Waheed, and Dr. Abraham Scaria, each with decades of ophthalmic gene therapy experience
• £96m ($120 million) in funding from lead investor Syncona and additional investors including Oxford Science Enterprises (OSE) to progress pipeline to key value inflection points

London and Oxford, UK, 12 June 2023 – Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, launches today and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including OSE, has provided £96 million ($120 million) to fund the acquisition of AGTC and provide capital to take each of Beacon Therapeutics’s development candidates through to value inflection points.

Beacon Therapeutics’s lead clinical asset is AGTC-501, a gene therapy program currently in Phase II clinical trials for the treatment of XLRP that was acquired as part of Syncona’s acquisition of AGTC in November 2022. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. Unlike other approaches in the space, AGTC-501 correctly expresses the full length RPGR protein, thereby addressing the entirety of photoreceptor damage caused by XLRP, including both rod and cone loss.

Beacon Therapeutics’s first pre-clinical asset is an intravitreally (IVT) delivered novel AAV based program for dry Age-related Macular Degeneration (dry AMD). Dry AMD is a leading cause of irreversible vision loss in people over 60, if left untreated. Around 20 million people in the United States suffer from AMD.

The second pre-clinical asset is targeting cone-rod dystrophy (CRD) which is caused by a null mutation in the Cadherin Related Family Member 1 (CDHR1) gene. The program has been licensed from the laboratory of Professor Robert MacLaren, Professor of Ophthalmology at the University of Oxford. Prof. MacLaren, a world leading retinal expert and an experienced biotech company founder and a Co-Founder of Beacon Therapeutics, will become a key scientific advisor to the company and will join the board of directors.

To bolster its pipeline in the future, Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space.

Beacon Therapeutics will be led by David Fellows, the former Chief Executive of Nightstar Therapeutics with over 40 years’ experience in the ophthalmology field. He will be joined by retinal expert Dr. Nadia Waheed as Chief Medical Officer, formerly from Gyroscope Therapeutics. Dr. Abraham Scaria also joins the team from AGTC as Chief Scientific Officer bringing 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials.

David Fellows, Chief Executive Officer of Beacon Therapeutics commented: “Beacon Therapeutics combines a broad development pipeline, a deep scientific foundation, a strong clinical network, and a highly experienced management team to drive forward a unique late-stage clinical and pre-clinical pipeline. With the 12-month data from our Phase II SKYLINE trial for AGTC-501 expected shortly and two highly innovative and differentiated pipeline assets for prevalent and rare blinding diseases, we are excited to be building a new leader in the ophthalmic gene therapy space.”

Chris Hollowood, CEO of Syncona Limited, the lead investor in Beacon Therapeutics commented: “By acquiring AGTC and combining its late-stage program with highly complementary and innovative science from the University of Oxford and elsewhere, we have created an exciting new gene therapy company in an area where we have a great breadth and depth of knowledge and expertise. We look forward to working closely with Beacon Therapeutics’ exceptional management team to advance these assets through the clinic and towards people suffering from debilitating retinal diseases.”

Professor Robert MacLaren, Professor of Ophthalmology, University of Oxford, and Co-Founder of Beacon Therapeutics commented: “I have dedicated many years to translating pioneering gene therapies from the lab through to clinical trial phase with the support of my team in the Nuffield Laboratory of Ophthalmology and NIHR Oxford Biomedical Research Centre (BRC). Beacon Therapeutics is quite unique in being a company that at launch is already underpinned by excellent clinical trial data. The company has both highly innovative retinal gene therapy programmes and the means to target them to the main causes of blindness in both the young and old.”

Katya Smirnyagina, Senior Partner, Life Sciences, Oxford Science Enterprises (OSE) added: “Beacon Therapeutics is truly an exciting new company built around an established scientific foundation and a wealth of experience in the gene therapy and ophthalmology space. We are delighted that expertise spun out from the University of Oxford will become a key component to drive the future success of the business that could bring significant change in the treatment of a broad range of retinal diseases that cause blindness.”

Broad ophthalmic development pipeline
The company’s lead clinical gene therapy program AGTC-501 has a strong body of clinical evidence targeting XLRP, an inherited rare form of retinitis pigmentosa that causes progressive vision loss in boys and young men. AGTC-501 demonstrated meaningful efficacy and a good safety profile in the recent Phase I/II HORIZON trial and expects to be publishing 12-month data from its Phase II SKYLINE trial in the second half of 2023. In addition, Beacon Therapeutics is awaiting feedback from the US Food and Drug Administration (FDA) regarding the study design of its upcoming VISTA clinical trial, a Phase II/III study to assess the effect of AGTC-501 on the symptoms of retinitis pigmentosa in additional patients with XLRP.

The first preclinical program features intravitreally (IVT) delivered gene therapy for dry AMD. IVT delivery provides access to a significantly greater number of patients than sub-retinal delivery as it can be administered within an outpatient clinic rather than requiring surgery.

The second preclinical program, CRD, targets mutations in the CDHR1 gene, which may cause central vision loss similar to dry AMD in older people and severe sight loss in younger patients.

The Company has a new location in London, UK, complementing existing facilities in Boston, Massachusetts and Alachua, Florida, US.

Contacts:
Beacon Therapeutics:
David Fellows, CEO
Email: info@beacontx.com

Consilium Strategic Communications:
Alex Harrison, Ashley Tapp
Email: Beacon@consilium-comms.com
Tel: +44 (0)20 3709 5700

About Beacon Therapeutics

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.

The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another in-licensed from the University of Oxford targeting cone-rod dystrophy (CRD), an inherited retinal disease.

Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss.

Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space.

The Company is supported by funds from Syncona and additional investors including Oxford Science Enterprises.

Find out more about us online at: www.beacontx.com.

GlobeNewswire Distribution ID 1000824663

นิวยอร์ก, June 12, 2023 (GLOBE NEWSWIRE) — Bitmanu มีความยินดีที่จะประกาศโปรโมชั่น 3 Plus 1 สำหรับชุดเครื่องขุด ASIC หลังจากที่ประสบความสำเร็จเมื่อไม่นานนี้ เครื่องขุด BM 1, BM 2 และ BM Pro ของบริษัทนี้ได้สร้างผลลัพธ์ที่ยอดเยี่ยมในตลาดด้วย Hash Rate สูงที่ไม่มีใครเทียบได้ โปรโมชั่นดังกล่าวที่เพิ่งเปิดตัวจะมีไปจนถึงวันที่ 10 กรกฎาคม โดยจะมอบอุปกรณ์ขุด 1 เครื่องฟรีให้แก่ผู้ซื้อทุกรายที่ซื้ออุปกรณ์ประเภทเดียวกัน 3 เครื่อง

Hash Rate ที่เหนือชั้น

	BM Pro	BM 2	BM 1
Bitcoin	3900 TH/s	1220 TH/s	760 TH/s
Litecoin	400 GH/s	128 GH/s	80 GH/s
Dash	75 TH/s	25 TH/s	15 TH/s
Monero	32 MH/s	10 MH/s	6 MH/s

Hash Rate นี้ส่งผลให้หลายต่อหลายคนต่างแนะนำว่า เครื่องขุด Bitmanu เป็นฮาร์ดแวร์การขุดที่ทรงพลังที่สุดเท่าที่เคยมีมา คำกล่าวนี้ยังได้รับการสนับสนุนจากข้อเท็จจริงที่ว่า ผลิตภัณฑ์ของ Bitmanu นั้นไม่ได้ใช้พลังงานอย่างบ้าคลั่งเหมือนกับอุปกรณ์ขุดอื่นๆ ส่วนใหญ่ในตลาด โดยเป็นเครื่องจักรที่ใช้พลังงานอย่างคุ้มค่าและช่วยให้ผู้ใช้ส่วนใหญ่สามารถเรียกเงินทุนทั้งหมดคืนได้ภายในเวลาไม่เกินหนึ่งเดือน

กำไรต่อเดือนที่เป็นไปได้

	BM Pro	BM 2	BM 1
Bitcoin	$7000	$2400	$2000
Litecoin	$10,000	$3200	$3000
Dash	$25,000	$9000	$5000
Monero	$22,000	$6400	$3800

โดยทั่วไปแล้วการขุดคริปโตหรือสกุลเงินดิจิทัลถือเป็นงานที่ซับซ้อน ซึ่งต้องใช้ความรู้และประสบการณ์ทางเทคนิคในระดับสูง ทำให้คนทั่วไปที่มีความรู้ทางด้านเทคนิคอย่างจำกัดไม่สามารถแข่งขันกับนักขุดอื่นๆ ในตลาดที่เกิดใหม่นี้ได้มากนัก อย่างไรก็ตาม เป็นที่สังเกตว่า ลูกค้าของ Bitmanu ในสัดส่วนที่สูงเป็นผู้ที่ไม่เคยใช้อุปกรณ์ขุดมาก่อน

Bitmanu จึงได้นำมาตรการที่สำคัญหลายประการมาใช้เพื่อให้ทุกคนทำกำไรจากการขุดสกุลเงินดิจิทัลได้ ประการแรก เครื่องขุดของ Bitmanu เป็นอุปกรณ์แบบ Plug-and-Play ที่สามารถเริ่มการขุดได้ทันทีที่เสียบปลั๊กไฟ นอกจากนี้ ความต้องการของระบบที่มีต่อผลิตภัณฑ์เหล่านี้ยังอยู่ในระดับเล็กน้อย จึงเหมาะอย่างยิ่งสำหรับผู้ที่ชื่นชอบการขุดแบบใช้เวลาน้อย

หากต้องการข้อมูลเพิ่มเติมเกี่ยวกับ Bitmanu โปรดไปที่ https://bitmanu.com/

เกี่ยวกับ Bitmanu: Bitmanu เป็นบริษัทผู้ผลิตที่สร้าง เป็นเจ้าของโดย และบริหารจัดการโดยทีมนักลงทุนและผู้เชี่ยวชาญที่มีชื่อเสียงในอุตสาหกรรมคริปโตหรือสกุลเงินดิจิทัล ซึ่งอุทิศตนเพื่อนำประโยชน์ของนวัตกรรมเทคโนโลยีล่าสุดมาสู่สาธารณชน บริษัทมีเครื่องขุดสกุลเงินดิจิทัลที่หลากหลายและให้ผลตอบแทนจากการลงทุนที่รวดเร็วเป็นพิเศษ และทุกคนสามารถตั้งค่าและใช้งานได้โดยไม่ต้องเป็นผู้เชี่ยวชาญหรือมีประสบการณ์มาก

Alex Torum
media@bitmanu.com
+1 347 973 5948

GlobeNewswire Distribution ID 1000824687